ClinicalTrials.gg

Program

linzagolix

Also written as “KLH-2109”, “75 mg linzagolix tablet” and “200 mg linzagolix tablet”.

Its studies are mostly in Endometriosis · Leiomyoma · Renal Insufficiency · Hepatic Insufficiency, led by 2 companies.

Furthest: phase 3, since Jun 6, 201914 company-led studies, 1 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kissei Pharmaceutical111 open or runningphase 3since Jun 6, 2019Jul 14, 2011Nov 2027phase 3 · NCT07015268
ObsEva30 open or runningphase 2since May 3, 2016May 3, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2011First study: phase 2 study in EndometriosisNew to Kissei PharmaceuticalKissei Pharmaceutical · NCT01395940 · 20 enrolled · Japan
  2. Feb 12, 2012Phase 2 study in EndometriosisKissei Pharmaceutical · NCT01533532 · 100 enrolled · Japan
  3. Jun 25, 2012Phase 2 study in EndometriosisKissei Pharmaceutical · NCT01629420 · 20 enrolled · Japan
  4. May 3, 2016ObsEva's first study: phase 2 study in EndometriosisNew to ObsEvaObsEva · NCT02778399 · 328 enrolled · United States, Poland, Russian Federation and more
  5. May 18, 2016Phase 2 study in EndometriosisKissei Pharmaceutical · NCT02778919 · Japan
  6. May 20, 20192 phase 1 studiesObsEva · NCT03961932, NCT03962049
  7. Jun 6, 20192 phase 3 studies in EndometriosisKissei Pharmaceutical · NCT03986944, NCT03992846
  8. Apr 3, 20202 phase 3 studies in EndometriosisKissei Pharmaceutical · NCT04335591, NCT04372121
  9. Jun 27, 20222 phase 3 studies in LeiomyomaKissei Pharmaceutical · NCT05445167, NCT05440383
  10. Jun 3, 2025Phase 3 study in EndometriosisKissei Pharmaceutical · NCT07015268 · 288 enrolled · Japan

Ahead

  1. Nov 2027Primary completion: phase 3 study in EndometriosisKissei Pharmaceutical · NCT07015268

TargetBeta

GNRHR →read by rule
“Gonadotropin-releasing hormone receptor antagonist; Gonadotropin-releasing hormone receptor antagonist”ChEMBL 37, by rule

Other programs on GNRHR

ProgramCompanyFurthest phaseStudies
LeuprolideruleTakedaphase 439
triptorelinruleIpsenphase 421
GoserelinruleAstraZenecaphase 414
GnRH Antagonist SHR7280Jiangsu HengRui Medicinephase 310
Gonadotropin-Releasing HormoneruleFerring Pharmaceuticalsphase 35
leuprolide mesylateruleforesee-pharmaceuticals-co-ltdphase 33

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07015268Endometriosis · Japan3Active, not recruitingKissei PharmaceuticalNov 2027288
NCT05445167Leiomyoma · Japan3CompletedKissei PharmaceuticalFeb 16, 202489
NCT05440383Leiomyoma · Japan3CompletedKissei PharmaceuticalAug 21, 2024287
NCT04372121Endometriosis · United States, Canada, Puerto Rico3TerminatedKissei PharmaceuticalJan 8, 202130
NCT04335591Endometriosis · United States, Austria, Bulgaria and more3CompletedKissei PharmaceuticalSep 15, 2022356
NCT03992846Endometriosis · United States, Austria, Bulgaria and more3CompletedKissei PharmaceuticalOct 18, 2021486
NCT03986944Endometriosis · United States, Canada, Puerto Rico3TerminatedKissei PharmaceuticalJan 6, 202185
NCT03962049Hepatic Insufficiency · United States1CompletedObsEvaOct 23, 201924
NCT03961932Renal Insufficiency · United States1CompletedObsEvaJan 22, 202033
NCT02778919Endometriosis · Japan2CompletedKissei PharmaceuticalMar 23, 2018
NCT02778399Endometriosis · United States, Poland, Russian Federation and more2CompletedObsEvaApr 2018328
NCT01629420Endometriosis · Japan2CompletedKissei Pharmaceutical20
NCT01533532Endometriosis · Japan2CompletedKissei Pharmaceutical100
NCT01395940Endometriosis · Japan2CompletedKissei Pharmaceutical20

How it is read

Names in the registry

  • “KLH-2109”, 11 entries
  • “75 mg linzagolix tablet”, 4 entries
  • “200 mg linzagolix tablet”, 4 entries
  • “Linzagolix”, 2 entries
  • “OBE2109”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.